3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
292
Urinary Bladder Neoplasms
39
Neoplasm Metastasis
35
Carcinoma, Non-Small-Cell Lung
24
Carcinoma, Transitional Cell
23
Neoplasms
21
Breast Neoplasms
20
Lung Neoplasms
13
Carcinoma, Renal Cell
13
Ovarian Neoplasms
12
Stomach Neoplasms
11
Squamous Cell Carcinoma of Head and Neck
11
Non-Muscle Invasive Bladder Neoplasms
10
Melanoma
9
Small Cell Lung Carcinoma
7
Salivary Gland Neoplasms
7
Prostatic Neoplasms, Castration-Resistant
7
Head and Neck Neoplasms
7
Esthesioneuroblastoma, Olfactory
7
Esophageal Neoplasms
7
Colorectal Neoplasms
7
Urethral Neoplasms
6
Uterine Cervical Neoplasms
5
Triple Negative Breast Neoplasms
5
Prostate Cancer Metastatic
5
Pancreatic Neoplasms
5
Metastatic Castration-resistant Prostate Cancer
5
Kidney Neoplasms
5
Adenocarcinoma
5
Sarcoma
4
Interventions
pembrolizumab
2
Nivolumab
2
Specimen Handling
1
Quality of Life
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Magnetic Resonance Spectroscopy
1
Ipilimumab
1
Immunotherapy
1
Imatinib Mesylate
1
GSK-3326595
1
Drug Therapy
1
Docetaxel
1
CTLA-4 Antigen
1
Biological Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Adenoid Cystic
×
Docetaxel
×
Genitourinary
×
Clear all
NCT04140526
2025-05-23
PRESERVE-001
OncoC4, Inc.
Phase 1/2
Active not recruiting
733 enrolled